IGN 002

Drug Profile

IGN 002

Alternative Names: Anti-CD20 monoclonal antibody+IFN (IGN002); IGN-002

Latest Information Update: 12 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunGene
  • Developer ImmunGene; The Leukemia & Lymphoma Society; Valor Biotherapeutics
  • Class Antineoplastics; Cytokines; Monoclonal antibodies; Proteins
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 02 May 2017 ImmunGene acquires IGN 002 from Valor Biotherapeutics
  • 27 Jul 2016 Valor Biotherapeutics, The Leukemia and Lymphoma Society and ImmuGene plan a phase II extension trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT02847949)
  • 01 Dec 2015 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT02519270)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top